CRUSH ReportsCRUSH Alerts 2.0CRUSH Industry ReportsCRUSHarmyContact Manager ApplicationMid-Market Manager ApplicationTarget Builder Application
 

Watson Pharmaceuticals (WPI)

The Watson Pharmaceuticals CRUSH Report is a Fortune 1000 deep dive sales intelligence company profile and will help increase your sales leads and add more accounts in your sales pipeline while eliminating costly research time.

The Watson Pharmaceuticals CRUSH Report contains insights to IT architectures, business and technology initiatives, corporate strategies, projects and budgets, org charts and key decision-maker contact info.

The Watson Pharmaceuticals CRUSH Report allows IT sales and marketing professionals to:
  • Jump-start sales cycles in net new accounts
  • Expand footprints in existing customer accounts
  • Facilitate the strategic account planning process
  • Respond to RFPs & bids more effectively
  • Build better content into executive level presentations
  • Identify the presence of competitors & partners
The Watson Pharmaceuticals CRUSH Report has the competitive intelligence needed for account planning within the Fortune 1000. Target the right people, with the right message at the right time using our org charts, decision maker contact info, business drivers and IT landscapes.

Click here to download free sample CRUSH Reports

Watson Pharmaceuticals News Release

A Collection of Watson Pharmaceuticals News Release

Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference
Friday May 18th 2012 04:05:53 PM

PARSIPPANY, N.J., May 18, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference on Wednesday, May 30, 2012 at 4:00PM Eastern Time at the Waldorf-Astoria Hotel in New York, New York.  The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com.  The webcast can also be accessed at the following URL: http://cc.talkpoint.com/bern001/053012a_ad/?e...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Watson Confirms Lo Loestrin® Fe Patent Challenge
Friday May 18th 2012 09:28:19 AM

- Paragraph IV Litigation Underway - PARSIPPANY, N.J., May 18, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Norethindrone Acetate/Ethinyl Estradiol and Ethinyl Estradiol and Ferrous Fumarate Tablets,1 mg/0.01 mg and 0.01 mg and 75 mg. Watson's ANDA product is a generic version of Warner Chilcott Company LLC's Lo Loestrin® Fe which is indicated for use by women to prevent pregnancy. Warner Chilcott Company, LLC filed suit against Watson on May 16, 2012, in the United S...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Watson Confirms Lialda® Patent Challenge
Wednesday May 9th 2012 04:05:49 PM

- Paragraph IV Litigation Underway - PARSIPPANY, N.J., May 9, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Mesalamine Delayed-release Tablets, 1.2g. Watson's ANDA product is a generic version of Shire Development LLC's Lialda®. Shire Development LLC, Shire Pharmaceutical Development Inc., Cosmo Technologies Limited, and Guiliani International Limited filed suit against Watson on May 8, 2012, in the United States District Court for the Southern Distric...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Watson Announces Formation of Global Integration Management Office to Support Pending Actavis Acquisition
Wednesday May 9th 2012 09:01:33 AM

- Marc Lehnen, Ph.D., Named Senior Vice President, Global Integration Management PARSIPPANY, N.J., May 9, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has created a Global Integration Management Office, reporting directly to Paul M. Bisaro, President and Chief Executive Officer, and focusing on planning and implementing the integration of Actavis, following the announcement of Watson's intention to acquire the Zug, Switzerland-based company.  Marc Lehnen, Ph.D., has been designated to lead the Global Integration Management Office in the newly created position of Senior Vice President, Global Integration Management. Dr. Lehnen will join Watson eff...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Friday May 4th 2012 04:00:09 PM

PARSIPPANY, N.J., May 4, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012 at 10:00 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com. The webcast can also be accessed at the following URL: http://www.veracast.com/webcasts/baml/healthcare2012/id16...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Watson Names Lisa DeFrancesco Vice President, Global Investor Relations
Friday May 4th 2012 09:00:57 AM

PARSIPPANY, N.J., May 4, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that Lisa M. DeFrancesco has been promoted to the position of Vice President, Global Investor Relations, effective immediately.  In this position, Ms. DeFrancesco reports to Charles Mayr, Chief Communications Officer – Global.  She succeeds Patricia Eisenhaur, who is leaving Watson on June 1, 2012. In this position, Ms. DeFrancesco is responsible for Watson's proactive global investor relations programs and serves as the principle spokesperson and point of contact with the analyst and investment community. She also provides current relevant business, competitor and financial communit...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Watson Pharmaceuticals To Webcast Annual Meeting Of Stockholders On May 11, 2012
Tuesday May 1st 2012 09:25:57 AM

PARSIPPANY, N.J., May 1, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI)  announced today that the Company will conduct a live webcast of its 2012 Annual Meeting of Stockholders on Friday, May 11, 2012 beginning at 9:00 AM Eastern Daylight Time.  As part of the meeting, Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business. The webcast can be accessed on Watson Pharmaceuticals' Investor Relations Website or directly at http://www.videonewswire.com/event.asp?id=86091. An archived version of the webcast will be available for 30 days beginning several hours after the live presentation concl...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Watson First Quarter 2012 Non-GAAP EPS Increases 84% to $1.64; Net Revenue Increases 74% to $1.5 Billion
Monday April 30th 2012 07:00:55 AM

- GAAP EPS $0.43, Compared to $0.36 Q1 2011 - - 70% Increase in Adjusted EBITDA - - Company Updates 2012 Forecast - PARSIPPANY, N.J., April 30, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net income for the first quarter 2012 increased 87 percent to $208.8 million or $1.64 per diluted share on a non-GAAP basis, compared to $111.9 million or $0.89 per diluted share in the first quarter 2011.  On a GAAP basis, net revenue increased 74 percent to $1.5 billion, compared to $876.5 million in the first quarter 2011. GAAP earnings per diluted share for the first quarter 2012 were $0.43, compared to $0.36 in the prior year period. For the first quarter 2...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Watson Announces Restructuring of Senior Leadership to Support Expanded Global Businesses
Friday April 27th 2012 09:00:49 AM

- Sigurdur Oli Olafsson Named President, Global Generics - G. Frederick Wilkinson Named President, Global Brands - Robert A. Stewart Named President, Global Operations - David A. Buchen Named Chief Legal Officer - Global - R. Todd Joyce Named Chief Financial Officer - Global - Charles M. Mayr Named Chief Communications Officer - Global - Patrick J. Eagan Named Senior Vice President Human Resources - Global PARSIPPANY, N.J., April 27, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has refined and expanded the responsibilities of its senior executive team, in recognition of the Company's continued glo...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Watson and Antares Announce the Introduction of Gelnique 3%(TM), for the Treatment of Overactive Bladder
Thursday April 26th 2012 07:07:43 AM

Gelnique 3%(TM) Available in US Pharmacies Beginning April 26 -- PARSIPPANY, N.J. and EWING, N.J., April 26, 2012 /PRNewswire via COMTEX/ --Watson Pharmaceuticals, Inc. (NYSE: WPI) and Antares Pharma, Inc. (NYSE Amex: AIS) today announced the launch of Gelnique 3%(TM) (oxybutynin) gel 3%, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency. Gelnique 3%(TM) is a clear, odorless topical gel that has been shown to be an effective and safe treatment for OAB. The product is available in a metered pump dispenser, offering patients convenient dosing. (Photo: http://photos.prnewswire.com/prnh/20120426/NY95340) OAB is a condition ...

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Decision Chain
Org Charts


Org Chart

Insights to Initiatives, Projects, & Budgets

Decision Maker Contact Info

Contact Info